Mucosis Receives Financial Support from the Dutch Government for its SynGEM Programme

Biotechnology company Mucosis BV has received an innovation credit line of up to €5 million from the Netherlands Enterprise Agency, an agency of the Dutch Ministry of Economic Affairs.

Mucosis will use these funds to further advance the clinical development of its proprietary SynGEM prefusion F RSV vaccine candidate through human proof-of-concept studies. These studies aim to demonstrate both safety and protection against a challenge with RSV in healthy volunteers.

"We are delighted to have the support of the Dutch government in such an important disease area. Combined with our recently announced strategic partnership with BCHT of China and new investment round, we have now raised over €10 million in the first half of 2014. Advancing the SynGEM programme to human clinical trials through these funds will create a substantial company value inflection point in the near term", said Thomas Johnston, CEO of Mucosis.  "In addition, we see this significant funding as a further validation of our clinical-stage Mimopath platform and its potential to combat the most challenging of infectious diseases.”